Compugen Ltd (NASDAQ: CGEN)’s stock price has soared by 1.15% in relation to previous closing price of $1.74. Nevertheless, the company has seen a gain of 7.98% in its stock price over the last five trading days. prnewswire.com reported 2025-06-12 that HOLON, Israel, June 12, 2025 /PRNewswire/ — Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced the presentation of AI/ML driven predictive computational research at upcoming international scientific conferences reflecting Compugen’s scientific capabilities in understanding complex cancer biology.
Is It Worth Investing in Compugen Ltd (NASDAQ: CGEN) Right Now?
CGEN has 36-month beta value of 2.63. Analysts have mixed views on the stock, with 4 analysts rating it as a “buy”, 0 as “overweight”, 0 as “hold”, and 0 as “sell”.
The public float for CGEN is 91.53M, and currently, short sellers hold a 1.60% ratio of that float. The average trading volume of CGEN on July 04, 2025 was 242.23K shares.
CGEN’s Market Performance
CGEN stock saw a decrease of 7.98% in the past week, with a monthly decline of -3.83% and a quarterly a decrease of 20.55%. The volatility ratio for the week is 5.91%, and the volatility levels for the last 30 days are 5.24% for Compugen Ltd (CGEN). The simple moving average for the past 20 days is 3.87% for CGEN’s stock, with a 4.03% simple moving average for the past 200 days.
Analysts’ Opinion of CGEN
Many brokerage firms have already submitted their reports for CGEN stocks, with Oppenheimer repeating the rating for CGEN by listing it as a “Outperform”. The predicted price for CGEN in the upcoming period, according to Oppenheimer is $4 based on the research report published on January 13, 2025 of the current year 2025.
Jefferies, on the other hand, stated in their research note that they expect to see CGEN reach a price target of $2. The rating they have provided for CGEN stocks is “Hold” according to the report published on August 05th, 2022.
Stifel gave a rating of “Buy” to CGEN, setting the target price at $19 in the report published on May 13th of the previous year.
CGEN Trading at 14.39% from the 50-Day Moving Average
After a stumble in the market that brought CGEN to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -33.83% of loss for the given period.
Volatility was left at 5.24%, however, over the last 30 days, the volatility rate increased by 5.91%, as shares surge +2.92% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +20.55% upper at present.
During the last 5 trading sessions, CGEN rose by +7.98%, which changed the moving average for the period of 200-days by -10.66% in comparison to the 20-day moving average, which settled at $1.6945. In addition, Compugen Ltd saw 0.57% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
N/A, the N/A of Compugen Ltd, N/A N/A shares at N/A during a trade that took place back on N/A, which means that N/A is holding N/A shares at N/A based on the most recent closing price.
Stock Fundamentals for CGEN
Current profitability levels for the company are sitting at:
- -0.54% for the present operating margin
- 0.7% for the gross margin
The net margin for Compugen Ltd stands at -0.51%. The total capital return value is set at -0.16%. Equity return is now at value -24.22%, with -12.35% for asset returns.
Currently, EBITDA for the company is -14.4 million with net debt to EBITDA at 0.8. When we switch over and look at the enterprise to sales, we see a ratio of 5.54. The receivables turnover for the company is 8.76for trailing twelve months and the total asset turnover is 0.24. The liquidity ratio also appears to be rather interesting for investors as it stands at 5.09.
Conclusion
To put it simply, Compugen Ltd (CGEN) has had a better performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
